Laidlaw downgrades Alaunos to Hold on ‘uncertain future’

Laidlaw analyst Yale Jen downgraded Alaunos Therapeutics to Hold from Buy without a price target following the company’s Q2 results. The analyst is “disappointed” with the “rather mild” efficacy shown by the SB TCR-T library in the solid tumor Phase I/II trial. When coupled with a “weak” financing environment, Alaunos has an “uncertain future,” the analyst tells investors in a research note.